QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.53
+0.69 (+2.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close27.84
Open28.86
Bid10.00 x 800
Ask36.22 x 800
Day's range27.62 - 29.22
52-week range9.47 - 43.23
Volume312,569
Avg. volume290,418
Market cap1.063B
Beta (3Y Monthly)-0.65
PE ratio (TTM)N/A
EPS (TTM)-2.47
Earnings date30 May 2017 - 2 Jun 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est50.22
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    uniQure to Participate in Multiple Upcoming Industry Conferences

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 28, 2018-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced ...

  • GlobeNewswire21 days ago

    uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

    LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --  uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs,  today announced that the third patient has been treated in the Company’s Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. AMT-061 has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicine (PRIME) regulatory initiative by the European Medicines Agency. The Phase IIb dose-confirmation study is an open-label, single-arm, single-dose trial being conducted in the United States to confirm the dose of AMT-061 prior to patient treatment in the ongoing Phase III HOPE-B pivotal trial.

  • Analyzing uniQure’s Valuation Trend
    Market Realistlast month

    Analyzing uniQure’s Valuation Trend

    Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.

  • uniQure: Its Promising Research Pipeline
    Market Realistlast month

    uniQure: Its Promising Research Pipeline

    It has a collaboration with Bristol-Myers Squibb (BMY) that’s targeted at cardiovascular disease. AMT-130 has received orphan drug designation in the United States and orphan medicinal product designation from the European Medicines Agency.

  • BioMarin Pharmaceutical and Its Promising Research Pipeline
    Market Realistlast month

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).

  • Implied Volatility Surging for uniQure (QURE) Stock Options
    Zackslast month

    Implied Volatility Surging for uniQure (QURE) Stock Options

    Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    Achillion Appoints Paul Firuta Chief Operating Officer

    Achillion Pharmaceuticals, Inc. (ACHN) today announced the appointment of Paul Firuta to the position of Executive Vice President and Chief Operating Officer effective immediately. “Paul’s operational leadership and successful track record launching rare disease treatments, including the complement inhibitor Cinryze®, will greatly benefit Achillion as we accelerate our factor D clinical programs and prepare for registrational trials and commercialization,” commented Joseph Truitt, President and Chief Executive Officer of Achillion.

  • GlobeNewswire2 months ago

    uniQure to Participate at Multiple Upcoming Conferences

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2018-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced ...

  • GlobeNewswire2 months ago

    uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 23, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has treated the first patient in its Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.  AMT-061 has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency. “The initiation of the AMT-061 dose-confirmation study is an important step toward our goal of advancing a potentially life-changing treatment for patients with hemophilia B,” said Robert Gut, M.D., Ph.D., chief medical officer of uniQure.  “I am extremely proud of the efforts made by the uniQure team to initiate this study, the objective of which is to demonstrate meaningful increases in FIX activity using the Padua variant and confirm dosing for the HOPE-B pivotal trial initiated this past June.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oaktree ...

  • UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
    Zacks2 months ago

    UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

    uniQure (QURE) delivered earnings and revenue surprises of 8.06% and -9.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    UniQure: 2Q Earnings Snapshot

    The Amsterdam-based company said it had a loss of 57 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswire2 months ago

    uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress

    ~Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061. ~First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061. ~Robert Gut, M.D., Ph.D., Named ...

  • 3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure
    Investor's Business Daily3 months ago

    3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure

    Gene therapy companies are looking to advance the technology, creating potentially curative treatments for genetic diseases.

  • Are These 3 Red-Hot Gene Therapy Stocks Still Buys?
    Motley Fool4 months ago

    Are These 3 Red-Hot Gene Therapy Stocks Still Buys?

    Is continued success in the cards for these biotech stocks?

  • 3 High-Growth Stocks That Could Soar
    Motley Fool5 months ago

    3 High-Growth Stocks That Could Soar

    Two e-commerce specialists head up this list of promising investment ideas.

  • First US drug priced at more than $1 million may be on the horizon
    CNBC5 months ago

    First US drug priced at more than $1 million may be on the horizon

    New gene therapies that aim to cure hemophilia, a disease affecting the blood's ability to clot, may carry prices of $1.5 million or more, analysts at Leerink wrote in a research note Monday.

  • 2 Cheap Growth Stocks to Buy Right Now
    Motley Fool5 months ago

    2 Cheap Growth Stocks to Buy Right Now

    These two clinical-stage biotechs could be absolute steals at current levels.